This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: BusinessWire
This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.

Global Circulating Tumor Cells (CTC) Market Analysis Report 2019 by Technology, Application and End-user - ResearchAndMarkets.com

January 25, 2019

DUBLIN--(BUSINESS WIRE)--Jan 25, 2019--The “Global Circulating Tumor Cells (CTC) Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

Further developments of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are driving the market growth.

However, factors such as lack of awareness and reluctance for the adoption of advanced CTC technologies are restricting the market growth.

The growing demand for faster diagnosis and innovation in CTC technology are offering significant growth opportunities for the market growth.

Based on Technology, the CTC Enrichment Methods segment attributed by advancements of enriched CTCs enable their functional characterization which is critical for disease interrogation and target therapy thus leading to raise the demand for enrichment technology.

High usage rates in biotechnology research establishments and high accuracy exhibited by this technology are some key factors expected to drive market growth in the forecast period.

Key Questions Answered in this Report:

How this market evolved since the year 2016 Market size estimations, forecasts and CAGR for all the segments presented in the scope Key Market Developments and financials of the key players Opportunity Analysis for the new entrants SWOT Analysis of the key players Fastest growing markets analysed during the forecast period

Technologies Covered:

CTC Detection Methods CTC Enrichment Methods Combined Enrichment and Separation of CTC (CTC Analysis)

Applications Covered:

Epithelial-Mesenchymal Transition (EMT) Biomarkers Development Cancer Cell Research Other Applications

End-users Covered:

Research & Academic Institutes Hospital & Clinics Diagnostic Centers

Companies Featured:

Thermo Fisher Scientific STEMCELL Technologies SRI International QIAGEN Hannover NanoString Technologies Inc. Miltenyi Biotec Menarini Silicon Biosystems Ikonisys Inc. Greiner Bio-One International GmbH GE Healthcare Fluxion Biosciences Inc. F. Hoffmann-La Roche Ltd. Biofluidica Microtechnologies LLC (US) Biocep Ltd. (Israel) ApoCell Inc. (US)

For more information about this report visit https://www.researchandmarkets.com/research/szzkf9/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190125005301/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biomarkers



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/25/2019 10:23 AM/DISC: 01/25/2019 10:23 AM